Publications

Publications

Publications

Evolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630

In this Perspective on the Science piece, published in the Journal of Cutaneous Oncology, we summarize a multidisciplinary discussion of the C-POST trial, which demonstrated improved disease-free survival with adjuvant cemiplimab in patients with resected high-risk cutaneous squamous cell carcinoma (CSCC). Participants reflected on evolving practice patterns and considered the contrasting futility outcome of adjuvant pembrolizumab in the KEYNOTE-630 study. To help explore potential reasons for these divergent results, this piece incorporates reconstructed survival data—estimates derived from published Kaplan-Meier curves in the absence of individual patient data. The discussion underscores both the enthusiasm and the remaining uncertainty surrounding adjuvant immunotherapy in CSCC.

David Michael Miller, MD, PhD, Vishal Anil Patel, MD, Vernon Keith Sondak, MD, Vatche Tchekmedyian, MD, Ross David Merkin, MD, Isaac Brownell, MD, PhD, Reed E. Drews, MD, Sameer Gupta MD, Nikhil I. Khushalani, MD, Paul T. Nghiem, MD, PhD, Howard Lane Kaufman MD, Kevin Scott Emerick MD

Perioperative Treatment Strategies for Advanced Melanoma and Non-Melanoma Skin Cancers

Perioperative therapies, including neoadjuvant and neoadjuvant plus adjuvant, are developing and promising approaches to improve management of cutaneous malignancies. This…

Kennedy H. Sun, Sach Thakker, Jonathan Greenzaid, Micah Belzberg, David M. Miller, Vishal A. Patel

Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain

In this Perspective on the Science piece, published in the Journal of Cutaneous Oncology, we provide a multidisciplinary summary and perspective on the CheckMate 358 trial in advanced Merkel cell carcinoma, exploring the role of dual checkpoint blockade, challenges of trial interpretation, real-world practice patterns, and evolving views on therapeutic intent and long-term outcomes.”

David Michael Miller, MD, PhD, Vernon Keith Sondak, MD, Sunandana Chandra, MD, Vatche Tchekmedyian, MD, Ryan J. Sullivan, MD, Ross David Merkin, MD, Vishal Anil Patel, MD, Adewole S. Adamson, MD, MPP, Isaac Brownell, MD, PhD, Reed E. Drews, MD, Nikhil I. Khushalani, MD, Shailender Bhatia, MD, Paul T. Nghiem, MD, PhD

The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities

This Perspective on the Science piece, published in the Journal of Cutaneous Oncology we discuss the evolving role of circulating tumor DNA (ctDNA) in the management of Merkel Cell Carcinoma, highlighting findings from a recent multicenter study and insights from a multi-institutional Journal Club. Key opportunities and challenges related to ctDNA’s use in surveillance and treatment decision-making are explored.

David Michael Miller, MD, PhD, Vernon Keith Sondak MD, Sunandana Chandra MD, Kenneth Y Tsai, Howard Lane Kaufman, Sameer Gupta MD, Isaac Brownell, Yoshine Saito, Ann W. Silk, Manisha Thakuria, Paul Nghiem MD, PhD

Immunotherapy for Advanced Conjunctival Squamous Cell Carcinoma: Treatment Failures

In this article, published in Ophthalmic Plastic and Reconstructive Surgery, we present a cohort study of patients treated with immunotherapy for advanced conjunctival SCC.

Azad Amee D, Zhang Jia Jia, Emerick Kevin S, Shalhout Sophia Z, Kaufman Howard L, Miller David M, Lee Nahyoung G, Yoon Michael K, Freitag Suzanne, Stagner Anna M, Wolkow Natalie

The Evolving Treatment Landscape for CSCC

This article, published in Archives of Dermatological Research, examines the evolving role of immunotherapy and dermatologists in CSCC treatment.

David Michael Miller, MD, PhD

Comparing First-Line Immunotherapy in Advanced Melanoma: No Clear Winner?

In this Perspective on Science piece, published in the Journal of Cutaneous Oncology, we reflect on the indirect treatment comparison analysis between RELATIVITY-047 and CheckMate 067 trial data.

Yoshine Saito, David Michael Miller, Isaac Brownell

Should Ipilimumab Be the New “Standard” for Refractory MCC?

In this editorial, published in the Journal of Cutaneous Oncology, we discuss the role of ipilimumab in anti-PD-1 refractory Merkel cell carcinoma. This topic was presented at the Third International Symposium for MCC in Houston, Texas on May 4th 2024.

David Michael Miller, MD, PhD

Tumor-Infiltrating Lymphocyte Therapy Receives FDA Approval

In this editorial, published in the Journal of Cutaneous Oncology, we reflect on the recent approval of the first cellular therapy for melanoma.

Jennifer Strong, David Michael Miller, MD, PhD, Isaac Brownell, MD, PhD

Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

In this article, published in JAMA Otolaryngology-Head & Neck Surgery, we present a cohort study of patients treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC

Kim EY, Ruiz ES, DeSimone MS, Shalhout SZ, Hanna GJ, Miller DM, Schmults C, Rettig EM, Foreman RK, Sethi R, Thakuria M, Silk Ann W

The Prognostic Value of the Merkel Cell Polyomavirus Serum Antibody Test: A Dual Institutional Observational Study

In this preprint, subsequently published in Cancer, we evaluate the prognostic value of the Merkel Cell Polyomavirus serum antibody test

David M. Miller MD PhD, Sophia Z. Shalhout PhD, Kayla Wright, Matt Miller, Howard L. Kaufman MD5, Kevin S. Emerick MD, Harrison Reeder PhD, Ann W. Silk MD, Manisha Thakuria MD

Perspectives on Medical Aid in Dying: A Multifaceted Ethical Discussion

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the complex ethical considerations surrounding Medical Aid in Dying, integrating insights from a recent multi-institutional journal club discussion.

David Michael Miller, MD, PhD, Isaac Brownell, MD, PhD, Vatche Tchekmedyian, MD, Fishal A. Patel, MD, Howard Lane Kaufman, MD, Kevin Scott Emerick, MD

Imaging Surveillance for Stage III Melanoma: Should We Be Stalkers or Casual Observers?

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the role of surveillance imaging for patients with high-risk melanoma.

Kevin Scott Emerick, MD, David Michael Miller, MD, PhD

A Closer Look: Evaluating Mohs Surgery’s Role in the Treatment of Invasive Melanoma of the Head and Neck

In this Perspectives on the Science piece, we reflect on the implications of the recently conducted multicenter study on the treatment of invasive head and neck melanoma using Mohs micrographic surgery.

Ching, Lauren, Strong, Jennifer, Lee, Truelian, Kaufman, Howard L., Emerick, Kevin S., Kim, Emily Y., Patel, Vishal A., Brownell, Isaac, Singh, Kritika, Neel, Victor A., Miller, David Michael, Gupta, Sameer

Adjuvant anti-PD-1 for Merkel Cell Carcinoma: Ready for the Clinic?

In this Perspectives on the Science piece we reflect on the recently published ADMEC-O trial.

David M. Miller, Jennifer Strong, Kevin S. Emerick, Sameer Gupta, Ann W. Silk, Isaac Brownell

To Screen or Not To Screen, That is the Question

In this Perspectives on the Science piece we reflect on the impact of the recent USPSTF recommendation statement on skin cancer screening.

Truelian Lee, David M. Miller, Howard L. Kaufman, Kevin S. Emerick, Sameer Gupta, Laura K. Ferris

Immunotherapy and Cardiovascular Health - A Cause for Concern?

In this Perspectives on the Science piece we reflect on the impact of ‘Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque’ by Drobni et al.

David M. Miller, Laura K. Ferris, Sameer Gupta, Isaac Brownell, Sophia Z. Shalhout

Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?

In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.

Serena Vilasi, David M. Miller, Howard L. Kaufman, Kevin S. Emerick, Sophia Z. Shalhout, Emily Y Kim, Vishal A. Patel, Khalid Garmen, Sameer Gupta, Isaac Brownell

Skin Cancer Chemoprevention for Transplant Recipients - The Search Continues

In this Perspectives on the Science piece, we reflect on the impact of the recently published ONTRANS trial.

Howard L. Kaufman, Vishal A. Patel, Sophia Z. Shalhout, Sameer Gupta, Sonia Cohen, Isaac Brownell, David M. Miller

Surgical Factors Affecting Regionally Metastatic Cutaneous Squamous Cell Carcinoma to the Parotid Gland

Understanding the impact of surgical treatment on regionally metastatic cutaneous squamous cell carcinoma (cSCC) is important as treatment paradigms shift with the introduction of immune checkpoint inhibitors. Herein, we aim to describe surgical impact on outcomes for regionally metastatic cSCC

Vishwanatha M. Rao, Allen L. Feng, Daniel G. Deschler, Howard Kaufman; Derrick T. Lin, David M. Miller, Jeremy D. Richmon, Sophia Z. Shalhout, Mark A. Varvares, Kevin S. Emerick

Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150.

In this Perspectives on the Science piece, we reflect on the impact of the recently published article by Ascierto et al. in Lancet Oncology that provides interim results from IMspire150.

David M. Miller, Kevin S. Emerick, Vishal A. Patel, Sonia Cohen, Isaac Brownell, Donald P. Lawrence

Targeting TBK1 to overcome resistance to cancer immunotherapy

We demonstrate that targeting TBK1 is a novel and effective strategy to overcome resistance to cancer immunotherapy.

Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, Sindurakar P, Tian J, Mehta A, Schneider AM, Yizhak K, Sade-Feldman M, LaSalle T, Sharova T, Xie H, Liu S, Michaud WA, Saad-Beretta R, Yates KB, Iracheta-Vellve A, Spetz JKE, Qin X, Sarosiek KA, Zhang G, Kim JW, Su MY, Cicerchia AM, Rasmussen MQ, Klempner SJ, Juric D, Pai SI, Miller DM, Giobbie-Hurder A, Chen JH, Pelka K, Frederick DT, Stinson S, Ivanova E, Aref AR, Paweletz CP, Barbie DA, Sen DR, Fisher DE, Corcoran RB, Hacohen N, Sorger PK, Flaherty KT, Boland GM, Manguso RT, Jenkins RW

Therapy with oncolytic viruses: progress and challenges

We review the available data and provide guidance on optimizing the use of oncolytic viruses in clinical practice.

Sophia Z. Shalhout, David M. Miller, Kevin S. Emerick, Howard L. Kaufman

Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma”.

Emily Y Kim, Sophia Z. Shalhout, Howard L. Kaufman, Kevin S. Emerick, Vishal A. Patel, Khalid Garmen, Isaac Brownell, David M. Miller

StoryboardR - An R Package and Shiny Application Designed to Visualize Real-World Data From Clinical Patient Registries

We created StoryboardR, an R package and Shiny application facilitates the data visualization of real-world data from tumor registries captured in REDCap^®.

David M. Miller, Sophia Z. Shalhout

Neoadjuvant Nivo/Rela for Resectable Melanoma

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article Neoadjuvant relatlimab and nivolumab in resectable melanoma.

David M. Miller, Howard L. Kaufman, Kevin S. Emerick, Justine V. Cohen, Emily Y Kim, Sophia Z. Shalhout

Ipi/Nivo for Advanced MCC

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel cell carcinoma - A Randomised, Open Label, Phase 2 Trial”.

Sophia Z. Shalhout, Justine V. Cohen, Khalid Garmen, Emily Y Kim, Sonia Cohen, David M. Miller

Neoadjuvant ICI for Resectable CSCC

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

David M. Miller, Vishal A. Patel, Justine V. Cohen, Khalid Garmen, Sophia Z. Shalhout

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

We present the results of a clinical pilot to standardize precision oncology workflows. This was published in The Oncologist in November 2022.

Dias-Santagata, Dora and Heist, Rebecca S et al.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

We present a prosepective study of neoadjuvant cemiplimab in high-risk resectable CSCC. This study was published in the New England Journal of Medicine in September 2022.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

Society guidelines for the management of NMSC. Published in the Journal for ImmunoTherapy of Cancer, July 2022.

A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma

We present a dual-institution retrospective study of Ipi/Nivo in refractory MCC. This was published in The Journal of Immunotherapy, July 2022.

Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes

We review the latest trends in cancer care for Nonmelanoma skin cancer. Published in Clinical Cancer Research, June 2022.

Sophia Z. Shalhout, Howard L. Kaufman, Kevin S. Emerick, David M. Miller

Generalizable EHR-R-REDCap Pipeline for a National Multi-Institutional Rare Tumor Patient Registry

We present a clinical informatics pipeline designed to capture large-scale structured laboratory EHR data.

BodyMapR - An R Package and Shiny Application Designed to Generate Anatomical Visualizations of Cancer Lesions

R package for enhanced visualizations of cancer lesions

David M. Miller, Sophia Z. Shalhout

Impact of an Evolving Regulatory Landscape on Skin Cancer Drug Development in the U.S

We present an analysis of the impact of an evolving regulatory landscape on skin cancer drug development.

Assessing Changes in Clinical Perineural Invasion during Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma

We report on the clinical experience of treating with immunotherapy for head and neck Cutaneous Squamous Cell Carcinoma.

Michael Wu, Katherine L Reinshagen, Mary Beth Cunnane, Sophia Z. Shalhout, Howard Kaufman, David M. Miller, Kevin S Emerick

The Merkel Cell Carcinoma Patient Registry-From Promise to Prototype to Patient

We present a white paper outlining the objectives and applications of the Merkel Cell Carcinoma Patient Registry.

Miller DM, Shalhout SZ, Saqlain F, Patel VA, Tsai Kenneth Y, Komandur R, Louv B, Wong MK

GENETEX - A GENomics Report TEXt Mining R Package and Shiny Application Designed to Capture Real-World Clinico-Genomic Data

We created GENETEX, an R package and Shiny application for text mining genomic reports from EHR and direct import into REDCap^®.

David M. Miller, Sophia Z. Shalhout

Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma - A single-institution cohort study

Journal: Journal of the American Academy of Dermatology (preprint). Accepted September 6, 2021. Please see the postprint on the JAAD Website.

Clinical Utility of Cell-free DNA Liquid Biopsies in Merkel Cell Carcinoma

An examination of the clinical utility of liquid biopsies in Merkel Cell Carcinoma.

Sophia Z. Shalhout, Kevin S. Emerick, Howard L. Kaufman, David M. Miller

Immunotherapy for Non-Melanoma Skin Cancer

We review the latest trends in cancer care for Non-Melanoma skin cancer.

Evaluation of clinical characteristics and pre-biopsy impressions of primary Merkel cell carcinoma of the skin

Journal: Dermatology Online Journal (postprint). Accepted August 13, 2021. © The Regents of the University of California, Davis campus. Please see the publisher’s version on…

Farees Saqlain, Sophia Z Shalhout, David M. Miller

Immune Checkpoint Inhibition in Marjolin Ulcer - A Case Series

We provide a case series in the Journal of Immunotherapy of response to anti-PD1 therapy in Marjolin Ulcer.

Sophia Z. Shalhout, Howard L. Kaufman, Ryan J. Sullivan, Donald Lawrence, David M. Miller

Commentary on Surgical Margins in MCC

We provide commentary on a recent publication in JAMA Dermatology entitled “Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma”.…

David M. Miller, Kevin Emerick

Microsatellitosis in Merkel cell carcinoma - a staging quandary

We provide an analysis in the Dermatology Online Journal of microsatellitosis in a cohort of MCC patients.

Farees Saqlain, Sophia Z. Shalhout, Kayla-Wright, David M. Miller

Real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma

In the JAAD, we provide a real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma.

Sophia Z. Shalhout, John Chul Park, Kevin S. Emerick, Ryan J. Sullivan, Howard L. Kaufman, David M. Miller

A REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology Clinic

We’re excited to share our recently published manuscript at JCO OP describing a REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous…

Farees Saqlain, Sophia Z. Shalhout, Keith T. Flaherty, Kevin S. Emerick, David M. Miller

Clinical landscape of oncolytic virus research in 2020

We provide an overview of the clinical landscap of oncolytic virus research.

Nicholas Macedo, David M. Miller, Rizwan Haq, Howard L Kaufman

Metastatic Merkel Cell Carcinoma Masquerading as multiple immune-related Adverse Events

We present a case of MCC masquerading as Multiple Immune-Related Adverse Events

Farees Saqlain, Sophia Z. Shalhout, Kevin S. Emerick, Thomas G. Neilan, Tatyana Sharova, David M. Miller

Regionally Metastatic Merkel Cell Carcinoma Associated with Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis

We present a case of MCC presenting with NMDA Receptor Encephalitis.

Sophia Z. Shalhout, Kevin S. Emerick, Peter M. Sadow, Jenny J. Linnoila, David M. Miller

TdT Expression Is a Marker of Better Survival in Merkel Cell Carcinoma, and Expression of B-Cell Markers Is Associated With Merkel Cell Polyomavirus

TdT expression is a potential marker of better survival in Merkel cell carcinoma.

Mai P Hoang, Piotr Donizy, Cheng-Lin Wu, Janusz Kopczynski, Malgorzata Pieniazek, David M. Miller, Janusz Ryś

Evaluation of the fragility of pivotal trials used to support FDA approval for plaque psoriasis

We evaluate the fragility of pivotal trials used to support FDA approval in Plaque Psoriasis.

Sophia Z. Shalhout, Romi Bloom, Lynn Drake, David M. Miller

Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance

We present a case of Acquired Cutis Laxa associated with Monocloncal Gammopathy of Monoclonal Significance.

Sophia Z. Shalhout, Myrna R. Nahas, Reed E. Drews, David M. Miller

Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity

Inhibition of Haspin kinase may overcome drug resistance in melanoma, modulate the immune environment and target a vulnerability in different cancer lineages.

Melms, Johannes C. and Vallabhaneni, Sreeram and Mills, Caitlin E. and Yapp, Clarence and Chen, Jia-Yun and Morelli, Eugenio and Waszyk, Patricia and Kumar, Sushil and Deming, Derrick and Moret, Nienke and Rodriguez, Steven and Subramanian, Kartik and Rogava, Meri and Cartwright, Adam N.R. and Luoma, Adrienne and Mei, Shaolin and Brinker, Titus J. and Miller, David M. and Spektor, Alexander and Schadendorf, Dirk and Riggi, Nicolo and Wucherpfennig, Kai W. and Sorger, Peter K. and Izar, Benjamin

Clinical spectrum of cutaneous melanoma morphology.

BACKGROUND: Melanoma can mimic other cutaneous lesions, but the full spectrum and prevalence of these morphologic variants remain largely unknown.
OBJECTIVE: To classify…

Klebanov, Nikolai, Gunasekera, Nicole S, Lin, William M, Hawryluk, Elena B, David M. Miller, Reddy, Bobby Y, Christman, Mitalee P, Beaulieu, Derek, Rajadurai, Suvithan, Duncan, Lyn M, Sober, Arthur J, Tsao, Hensin

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

We present a case of Eczema Tvecium secondary to T-Vec

David M. Miller, Ryan M. Trowbridge, Anupam Desai, Reed E. Drews

High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma

Cutaneous melanoma is an aggressive tumor that accounts for most skin cancer deaths. Among the physiological barriers against therapeutic success is a strong survival…

Eliades, Philip and Abraham, Brian J. and Ji, Zhenyu and Miller, David M. and Christensen, Camilla L. and Kwiatkowski, Nicholas and Kumar, Raj and Njauw, Ching Ni and Taylor, Michael and Miao, Benchun and Zhang, Tinghu and Wong, Kwok-Kin and Gray, Nathanael S. and Young, Richard A. and Tsao, Hensin

A Complete Response in cSCC with Ipi/Nivo

Although most cases of metastatic cutaneous Squamous Cell Carcinoma mCSCC can be cured with local therapy, up to 8,000 deaths occur each year. With no US Food and Drug…

David M. Miller, Faulkner-Jones, B. E., Stone, J. R., Drews, R. E.

Somatic Driver Mutations in Melanoma

Somatic driver mutations in melanoma.

Bobby Reddy, David M. Miller, Hensin Tsao

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

We present a novel multi-CDK inhibitor that restricts melanoma growth

Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H.

Molecularly Targeted Therapies and Immunotherapies For Melanoma

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.

Miller DM, Flaherty KT, Tsao H

CDKs as Therapeutic Targets in Melanoma

Cyclin-dependent kinases as therapeutic targets in melanoma. Miller and Flaherty (2014)

David M. Miller, Keith T Flaherty

Molecular testing in melanoma

We present an overview of the role of molecular testing in melanoma

David M. Miller, Keith T. Flaherty, Hensin Tsao

Parameters for Establishing Humanized Mouse Models

Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice…

Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, Burzenski L, Gott B, Foreman O, Kavirayani A, Herlihy M, Rossini AA, Shultz LD, Greiner DL.

TLR Activation Abrogates Mixed Chimerism

TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance.

Miller DM, Thornley T, Pearson T, Yamazaki M, Brehm MA, Rossini AA, Greiner DL.

Viral infection - a potent barrier to transplantation tolerance

Viral infection: a potent barrier to transplantation tolerance.

Miller DM, Thornley T, Rossini AA, Greiner DL

TLR Agonists Abrogate Immunological Tolerance

TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.

Miller DM, Thornley TB, Pearson T, Kruger AJ, Yamazaki M, Shultz LD, Welsh RM, Brehm MA, Rossini AA, Greiner DL

Role of Innate Immunity in Transplantation Tolerance

Role of Innate Immunity in Transplantation Tolerance.

Miller DM, Rossini AA, Greiner DL

Different mechanisms control peripheral and central tolerance

Different mechanisms control peripheral and central tolerance in hematopoietic chimeric mice. Yamazaki et al. (2007)

Yamazaki, M., T. Pearson, M. A. Brehm, D. M. Miller, J. A. Mangada, T. G. Markees, L. D. Shultz, J. P. Mordes, A. A. Rossini, and D. L. Greiner.

Jellypin - a lower eukaryotic serine proteinase inhibitor (serpin)

Identification and activity of a lower eukaryotic serine proteinase inhibitor (serpin) from Cyanea capillata: analysis of a jellyfish serpin, jellypin. Cole et al. (2004)

Cole, Elisabeth B. and Miller, David and Rometo, David and Greenberg, Robert M. and Brömme, Dieter and Çataltepe, Sule and Pak, Stephen C. and Mills, David R. and Silverman, Gary A. and Luke, Cliff J.

The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases

The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases.

Al-Khunaizi M1, Luke CJ, Askew YS, Pak SC, Askew DJ, Cataltepe S, Miller D, Mills DR, Tsu C, Brömme D, Irving JA, Whisstock JC, Silverman GA